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Abstract
Upon inflammation, circulating monocytes leave the bloodstream and migrate into the tis-
sues, where they differentiate after exposure to various growth factors, cytokines or infec-
tious agents. The best defined macrophage polarization types are M1 and M2. However,
the platelet-derived CXC chemokine CXCL4 induces the polarization of macrophages into a
unique phenotype. In this study, we compared the effect of CXCL4 and its variant CXCL4L1
on the differentiation of monocytes into macrophages and into immature monocyte-derived
dendritic cells (iMDDC). Differently to M-CSF and CXCL4, CXCL4L1 is not a survival factor
for monocytes. Moreover, the expression of the chemokine receptors CCR2, CCR5 and
CXCR3 was significantly higher on CXCL4L1-treated monocytes compared to M-CSF- and
CXCL4-stimulated monocytes. IL-1 receptor antagonist (IL-1RN) expression was upregu-
lated by CXCL4 and downregulated by CXCL4L1, respectively, whereas both chemokines
reduced the expression of the mannose receptor (MRC). Furthermore, through activation of
CXCR3, CXCL4L1-stimulated monocytes released significantly higher amounts of CCL2
and CXCL8 compared to CXCL4-treated monocytes, indicating more pronounced inflam-
matory traits for CXCL4L1. In contrast, in CXCL4L1-treated monocytes, the production of
CCL22 was lower. Compared to iMDDC generated in the presence of CXCL4L1, CXCL4-
treated iMDDC showed an enhanced phagocytic capacity and downregulation of expression
of certain surface markers (e.g. CD1a) and specific enzymes (e.g. MMP-9 and MMP-12).
CXCL4 and CXCL4L1 did not affect the chemokine receptor expression on iMDDC and
cytokine production (CCL2, CCL18, CCL22, CXCL8, IL-10) by CXCL4- or CXCL4L1-differ-
entiated iMDDC was similar. We can conclude that both CXCL4 and CXCL4L1 exert a direct
effect on monocytes and iMDDC. However, the resulting phenotypes are different, which
suggests a unique role for the two CXCL4 variants in physiology and/or pathology.
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Introduction
Monocytes and macrophages are critically important in the regulation of innate and adaptive
immune responses by generation of inflammatory mediators, antigen presentation, phagocyto-
sis and killing of microorganisms. In contrast to resident tissue macrophages, which are long-
living cells, monocytes in the circulation normally live for just a few days before undergoing
apoptosis, a process finely tuned by caspases [1,2]. In the tumor microenvironment and in
chronic inflammatory diseases, inhibition of the apoptotic program promotes monocyte sur-
vival, contributing to the accumulation of macrophages and the persistence of an inflammatory
milieu. In vitro, the macrophage colony-stimulating factor (M-CSF) inhibits apoptotic processes
and promotes the differentiation of monocytes into resting macrophages [3,4]. In response to
different microenvironmental cues macrophages can adopt a polarized phenotype, exemplified
in the M1/M2 paradigm [5]. Classical macrophages, also alluded to as M1 macrophages for
their ability to assist in a T helper-1 (Th1) immune response, are induced by interferon-γ (IFN-
γ) in combination with pathogen-derived signals (such as lipopolysaccharide; LPS) or pro-
inflammatory cytokines (interleukin-1β; IL-1β and/or tumor necrosis factor-α; TNF-α), and are
characterized by the production of significant amounts of inflammatory cytokines (IL-1β, IL-6,
IL-12, IL-23, TNF-α) and reactive oxygen and nitrogen species [5,6]. On the contrary, alterna-
tively activated or M2 macrophages evolve upon interaction with IL-4/IL-13, support Th2
responses [6,7] and promote fibrosis and tissue remodeling, via the production of transforming
growth factor β (TGF-β) and matrix metalloproteinases (MMPs), respectively. M2 macrophages
are characterized by high levels of scavenger-, mannose- and galactose-type receptors, reduced
production of pro-inflammatory mediators, and contribute to angiogenesis by secreting vascu-
lar endothelial growth factor (VEGF) [5,7,8]. In vivo evidence has shown that in many inflam-
mation-associated diseases, including cancer, infectious and allergic conditions, macrophages
behave as plastic cells modifying in time and space their expression and transcription profile
along a continuous spectrum, having M1 and M2 macrophage phenotypes as extremes [9,10].
During acute vascular injury or chronic disease, activated platelets have been recognized to
play an important role in the activation of monocytes, e.g. by the release of pro-inflammatory
cytokines, such as IL-1, or chemokines, such as RANTES/CCL5, platelet factor-4 (PF-4)/
CXCL4 and its variant CXCL4L1 [11,12]. CXCL4 forms heterodimers with classical growth
factors and other chemokines, binds with high affinity to glycosaminoglycans [13,14], and has
been shown to act via the CXCR3 splice variants, CXCR3A and CXCR3B, on T lymphocytes
and microvascular endothelial cells, respectively [15–17]. CXCL4 also protects monocytes
from spontaneous apoptosis and induces their differentiation into a distinct macrophage sub-
type, alluded to as M4 macrophages [18–20]. CXCL4-induced macrophages have a unique
transcriptome distinct from both M1 and M2 macrophages, characterized by low expression
of HLA-DR and lack of CD163 expression [18–21]. Of note, CXCL4-dependent loss of CD163
expression is irreversible, suggesting that CXCL4-induced macrophages represent a final stage
of cell differentiation, in contrast to M1 or M2 polarized macrophages [20]. The impact of
CXCL4 on the regulation of cell growth has been shown in many other reports, demonstrating
the inhibition of tumor growth and angiogenesis by CXCL4 [22–25]. Moreover, the CXCL4
variant CXCL4L1, isolated from thrombin-stimulated platelets and differing from authentic
CXCL4 in three carboxy-terminally located amino acids, was found to be more potent than
CXCL4 in inhibiting angiogenesis and tumor growth [26,27].
In this study, the effects of CXCL4 and its variant CXCL4L1 were investigated on the differ-
entiation of monocytes into macrophages and immature monocyte-derived dendritic cells
(iMDDC), by comparing the expression of several markers and chemokine/cytokine produc-
tion. Finally, phagocytosis of S. aureus by CXCL4- or CXCL4L1-treated iMDDC was evaluated.
CXCL4L1 and CXCL4 Act Differently on Myeloid Cells
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Materials and Methods
Reagents
Human recombinant macrophage colony-stimulating factor (M-CSF), IL-4, granulocyte mac-
rophage colony-stimulating factor (GM-CSF) and CXCL4 were purchased from Peprotech
(Rocky Hill, NJ, USA). Natural human CXCL4 was isolated from stimulated platelets as previ-
ously described [26]. Recombinant human CXCL4L1 was produced in insect cells and purified
by a 4-step chromatographic procedure [17]. The ATPlite assay kit was obtained from Perkin
Elmer (Boston, MA, USA). pHrodo red S. aureus bioparticles were obtained from Molecular
Probes (Eugene, OR, USA). The CXCR3 antagonist AMG487 was purchased from R&D Sys-
tems (Minneapolis, MN).
Cells
Human CD14+ monocytes were isolated from buffy coats derived from healthy donors (Blood
Transfusion Center, Mechelen, Belgium) as described [28]. To induce the differentiation of
monocytes into macrophages, CD14+ monocytes were suspended at a concentration of 2x106
cells/ml in RPMI1640 medium (Lonza, Verviers, Belgium) supplemented with 10% fetal calf
serum (FCS; Hyclone, Cramlington, UK) and gentamycin (50 μg/ml) and cultured in 6-well
plates (2 ml/well). The stimuli (M-CSF, CXCL4 or CXCL4L1) were added on the first day of
culture to obtain the different types of macrophages (Fig 1). Immature monocyte-derived den-
dritic cells (iMDDC) were generated by incubating purified human peripheral blood CD14+
monocytes in 6-well plates at 1x106 cells/ml (2 ml/well) in RPMI1640 medium containing 10%
FCS, 50 ng/ml GM-CSF and 20 ng/ml IL-4 for 6 days. On day 0 (iMDDC B) or day 4 (iMDDC
A), 200 μl medium containing different concentrations of CXCL4 or CXCL4L1 was added to
the MDDC cultures (Fig 1). On day 6 of culture, supernatants were collected to determine
cytokine levels by ELISA. The macrophages and iMDDC were collected from the 6-well plates
by pipetting up and down. Subsequently, phosphate buffered saline (PBS) was added to each
well (1 ml/well) and the remaining cells were detached through incubation for 10 min at 4˚C.
Cells were centrifuged and resuspended in the corresponding buffer to perform RNA extrac-
tion, phagocytosis assays, and flow cytometry.
Flow cytometry analysis
Expression of surface molecules and chemokine receptors on macrophages, iMDDC A or
iMDDC B after 6 days of culture was analyzed by flow cytometry. Cells were washed in PBS
and suspended in Zombie Aqua viability dye (1 μl/1 x 106 cells; BioLegend, San Diego, CA,
USA) for 15 min to exclude dead cells from the analysis. Afterwards, cells were washed and
incubated for 10 min at 4˚C with FACS buffer (PBS + 2% FCS) to block the Fc receptors and
subsequently stained (30 min on ice) with the following monoclonal anti-human antibodies:
allophycocyanin (APC) mouse CD1a (clone HI149), APC mouse CD14 (clone 63D3) and phy-
coerythrin (PE) mouse CXCL16 (clone 22-19-12) obtained from Biolegend, PE mouse CD163
(clone GHI/61), fluorescein (FITC) mouse HLA-DR (clone LN3) purchased from eBioscience
(San Diego, CA, USA), PE mouse CD80 (clone L307.4), PE mouse CD86 (clone 2331), APC
mouse CD11b (clone ICRF44), BV421 mouse CXCR3 (clone 1C6; this antibody does not dis-
criminate between CXCR3A and CXCR3B), BV421 mouse CCR5 (clone 2D7), BV421 mouse
CCR2 (clone 48607), Alexa Fluor 647 mouse CCR1 (clone 53504), PE mouse MSR1/CD204
(clone U23-56), APC mouse CD36 (clone CD38) and FITC mouse CD209/DC-SIGN (clone
DCN46) from BD Biosciences (Heidelberg, Germany). Thereafter, cells were washed twice
and fixed with 0.4% formaldehyde in FACS buffer. Acquisition was performed using an
CXCL4L1 and CXCL4 Act Differently on Myeloid Cells
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LSRFortessa X-20 cell analyzer (BD Biosciences) and data were analyzed using FlowJo software
(Tree Star, Ashland, OR, USA).
Gene expression studies
Relative changes in gene expression were evaluated by quantitative polymerase chain reactions
(qPCR). Total RNA extraction was performed with the RNeasy Mini Kit (Qiagen, Venlo, The
Netherlands) according to the manufacturer’s protocol. Afterwards, RNA quantification was
achieved using the Nanodrop2000 (Thermo Scientific, Waltham, MA, USA) and for each sam-
ple the same amount of total RNA was reverse transcribed into cDNA using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Relative changes in
gene expression were evaluated by qPCR using the TaqMan Fast Universal PCR master mix
(Applied Biosystems) and commercially available primers and probes (Table 1). Sample mixes
were loaded on a 96-well MicroAmp plate (Applied Biosystems) and were analyzed on the
7500 Fast Real-time PCR system. Obtained Ct values were processed following the 2-ΔΔCt
method, with 18S ribosomal 1 RNA (RN18S1) serving as housekeeping gene [29].
ELISA
Cytokine levels (e.g. CCL22/MDC, CCL18/PARC, IL-10, TNF-α, IL-1β) in cell culture super-
natants (sampled 6 days after culture initiation) of iMDDC and macrophages were determined
using ELISA according to instructions from the manufacturer (R&D systems). The CXCL8/
Fig 1. Treatment schedules of CD14+ monocytes to generate macrophages or immature dendritic cells.
CD14+ monocytes were cultured in the presence of M-CSF (30 ng/ml), CXCL4 (1 and 10 μg/ml) or CXCL4L1 (1 and
10 μg/ml) to differentiate into macrophages. For the differentiation into dendritic cells, CD14+ monocytes were
cultured in the presence of GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). On day 4 (iMDDC A) or day 0 (iMDDC B),
different concentrations of CXCL4 (1 and 10 μg/ml) or CXCL4L1 (0.1, 1 and 10 μg/ml) were added.
doi:10.1371/journal.pone.0166006.g001
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IL-8-, CCL3/MIP-1α- and CCL2/MCP-1-specific ELISAs were developed in our laboratory
[30].
Phagocytosis assay
Immature MDDC (1.5x106 cells/ml, 100 μl/sample) were incubated for 30 min at 37˚C with
33 μl/sample of pHrodo red S. aureus bioparticles, previously resuspended in Live Cell Imaging
solution (Molecular Probes). Cells were then washed in FACS buffer, fixed in FACS buffer
containing 0.4% formaldehyde, and the pHrodo fluorescence in iMDDC was analyzed by flow
cytometry. The phagocytic activity was quantified by first subtracting the background fluores-
cence (determined by incubating cells with bioparticles at 4˚C) and subsequently, the net fluo-
rescence for CXCL4- and CXCL4L1-treated iMDDC was divided by the net fluorescence of
control iMDDC (differentiated with GM-CSF/IL-4 without addition of chemokine).
Statistical analysis
Data were first analyzed by the non-parametric Kruskal-Wallis test (Statistica 12.0) for com-
parison of multiple (n>2) groups before performing pairwise comparisons. The Mann-
Table 1. Primer and probe sequences for evaluated genes.
Gene Primers (5’➔3’) Probe (5’➔3’)
RN18S1 ATCGCTCCACCAACTAAGAAC /5HEX/ACCACCCAC/ZEN/GGAATCGAGAAAGAG/3IABkFQ/
ACGGACAGGATTGACAGATTG
CCL2 CCTCTGCACTGAGATCTTCC /56-FAM/ATAGCAGCC/ZEN/ACCTTCATTCCCCAA/3IABkFQ/
GCCTCCAGCATGAAAGTCT
VEGFA TGAACTTCACCACTTCGTGAT /56-FAM/TGCTCTACC/ZEN/TCCACCATGCCAAG/3IABkFQ/
CCATGAACTTTCTGCTGTCTTG
NOS2 GCAGCTCAGCCTGTACT /56-FAM/TATTCAGCT/ZEN/GTGCCTTCAACCCCA/3IABkFQ/
CACCATCCTCTTTGCGACA
HMOX1 AGAATCTTGCACTTTGTTGCTG /5HEX/AGCTGCTGA/ZEN/CCCATGACACCAAG/3IABkFQ/
CGTTCCTGCTCAACATCCA
MMP-2 CAGACTTTGGTTCTCCAGCTT /56-FAM/CACCCTTGA/ZEN/AGAAGTAGCTGTGACCG/3IABkFQ/
ATCGAGATGCCTGGAATG
MMP-8 AGCGAGCCCCAAAGAATG /5HEX/TGTAATTTG/ZEN/CGGAGGTGTTGGTCCA/3IABkFQ/
TCCTTGCTCATGCCTTTCAG
MMP-9 CGTCGAAATGGGCGTCT /56-FAM/CCAGGAGGA/ZEN/AAGGCGTGTGC/3IABkFQ/
ACATCGTCATCCAGTTTGGTG
MMP-12 AATCTCGTGAACAGCAGTGAG /5HEX/AAGTTTGTG/ZEN/CCTCCTGAATGTGTAGTCC/3IABkFQ/
CCTGGATCTGGCATTGGAG
CXCR3A ACCCAGCAGCCAGAGCACC /56-FAM/TGAGTGACC/ZEN/ACCAAGTGCTAAATGACGC/3IABkFQ/
TCATAGGAAGAGCTGAAGTTCTCCA
CXCR3B TGCCAGGCCTTTACACAGC /5HEX/CCCGTTCCC/ZEN/GCCCTCACAGG/3IABkFQ/
TCGGCGTCATTTAGCACTTG
MRC1 TCCATCTTCCTTGTGTCAGC /56-FAM/TTCATGAGT/ZEN/AGGTTTAGCATCAATAATTTTTGGTCTTT/3IABkFQ/
GGTTTTGGAGTAATATTCACTGTTCT
IL1RN TTGTCCTGCTTTCTGTTCTCG /56-FAM/TCAGTGATG/ZEN/TTAACTGCCTCCAGCTG/3IABkFQ/
CTGTCCTGTGTCAAGTCTGG
All primer/probe sets were supplied as PrimeTime qPCR assays by Integrated DNA Technologies (IDT).
doi:10.1371/journal.pone.0166006.t001
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Whitney U test and Sign test were used to compare data from two unpaired or paired groups,
respectively.
Results
CXCL4, but not CXCL4L1, promotes macrophage survival
It has been described that chemokines, in particular the platelet-derived CXC chemokine
CXCL4, are involved in polarization and survival of monocytes [19]. CXCL4 stimulates mono-
cyte survival and induces polarization into macrophages with a unique transcriptome [19].
However, the effect of CXCL4L1 on monocyte differentiation has never been determined.
Therefore, human CD14+ monocytes were cultured for 6 days in the presence of CXCL4L1 (1
and 10 μg/ml). CXCL4 (1 and 10 μg/ml) and M-CSF (30 ng/ml) were included as control mac-
rophage survival factors (Fig 1). In contrast to M-CSF (30 ng/ml) and CXCL4 (10 μg/ml),
CXCL4L1 (1 and 10 μg/ml) did not stimulate monocyte survival (Fig 2). Microscopic analysis
demonstrated that, after 6 days in culture, monocytes stimulated with 30 ng/ml M-CSF or with
10 μg/ml CXCL4 showed a normal cell density and a morphology characteristic of macro-
phages, whereas CD14+ monocytes stimulated with CXCL4L1 (1 and 10 μg/ml) were far less
numerous and their numbers were comparable to those of unstimulated monocytes (Fig 2A
and data not shown). Flow cytometry with the Zombie Aqua dye showed a lower % of living
cells when CD14+ monocytes were treated with 1 or 10 μg/ml CXCL4L1 (i.e. 6.8±4.4% and 9.5
±3.1%, respectively, p<0.005) compared to 30 ng/ml M-CSF (i.e. 47.7±6.4%) or 10 μg/ml
CXCL4 (i.e. 56.4±5.7%) (Fig 2B). When the amount of intracellular ATP, which is a good
parameter for cell viability and metabolic activity and thus the cell number in cultures, was
quantified using an ATP assay kit, the number of macrophages after stimulation with
CXCL4L1 (1 and 10 μg/ml) or 1 μg/ml CXCL4 was significantly lower compared to cell num-
bers in cultures treated with 10 μg/ml CXCL4 or 30 ng/ml M-CSF (Fig 2C). Moreover,
CXCL4L1 (10 μg/ml) statistically inhibited macrophage survival induced by CXCL4 (10 μg/
ml) (Fig 2D).
CXCL4- and CXCL4L1-treated monocytes express different levels of
metalloproteinases and chemokine receptors
In order to get insight in the transcriptome of CXCL4L1-stimulated monocytes, human
CD14+ monocytes were exposed to M-CSF (30 ng/ml), CXCL4 (10 μg/ml) or CXCL4L1 (1 and
10 μg/ml) for 6 days. RNA was then extracted and the expression levels of several MMPs, the
established M1/M2 markers (i.e. iNOS and HMOX1), the IL-1 receptor antagonist (i.e. IL-
1RN), the IL-1 receptor, type II (IL-1R2), the mannose receptor (MRC), as well as both splice
variants of the CXCR3 receptor, were assessed by qPCR (Fig 3). Among the MMPs, MMP-9
showed significantly higher expression in CXCL4- and CXCL4L1 (1 μg/ml)-stimulated mono-
cytes as compared to M-CSF-treated monocytes, with even significantly higher expression in
CXCL4-treated monocytes compared to CXCL4L1-treated monocytes. Unlike the upregula-
tion of MMP-9, we found a downregulation of MMP-2 expression in CXCL4-induced macro-
phages, whereas MMP-2 expression was slightly increased in CXCL4L1-treated monocytes.
MMP-12 expression was below detection limit (data not shown), but we found significantly
increased expression of MMP-8 in both CXCL4L1- and CXCL4-treated monocytes as com-
pared to resting macrophages. We confirmed previous observations indicating that CXCL4
suppresses expression of the M2 marker heme oxygenase-1 (HMOX1) [20]. On the contrary,
we found that HMOX1 expression was significantly increased in CXCL4L1-treated monocytes.
In contrast to previous reports [19], we also observed a significant downregulation of the M1
CXCL4L1 and CXCL4 Act Differently on Myeloid Cells
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Fig 2. In contrast to CXCL4L1, CXCL4 induces morphological changes in monocyte-derived macrophages
and promotes their survival. CD14+ monocytes were cultured in the presence of M-CSF (30 ng/ml), natural
CXCL4 (1 and 10 μg/ml), recombinant CXCL4L1 (1 and 10 μg/ml) (panel A-C) or a combination of CXCL4 (10 μg/
ml) and CXCL4L1 (1 and 10 μg/ml) (panel D). Panel A reports bright field pictures illustrating the morphology of
monocyte-derived macrophages after 6 days of culture (20x magnification; scale bar 10μm). Panel B: After 6 days
of culture cells were stained with the viability dye Zombie Aqua before flow cytometry analysis. Dot plots (forward
scatter versus fluorescence) from one representative experiment out of 8 are shown. The gate circles the living
cells. Numbers indicate the % of viable cells in the sample. Panel C and D report quantification of monocyte-derived
macrophages after 6 days of culture by the ATP lite assay. The obtained luminescence values were normalized
relative to the luminescence value obtained after culture in the presence of M-CSF (dashed line). Results are shown
as mean ± SEM from 6–9 independent experiments. ***p<0.001; Mann-Whitney U test (CXCL4 or CXCL4L1
versus M-CSF) - †††p<0.001; Mann-Whitney U test (CXCL4 versus CXCL4L1 at identical concentrations)
—
$p<0.05; Sign test [CXCL4 (10 μg/ml) versus the combination of CXCL4 (10 μg/ml) plus CXCL4L1 (10 μg/ml)].
doi:10.1371/journal.pone.0166006.g002
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marker inducible nitric oxide synthase iNOS enzyme in CXCL4-differentiated monocytes,
which was also evident in CXCL4L1-treated (10 μg/ml) monocytes.
Fig 3. Effects of CXCL4 and CXCL4L1 on the matrix metalloproteinase and chemokine receptor gene
expression in differentiated monocyte-derived macrophages. Relative expression of iNOS, HMOX1, MMP-2,
MMP-8, MMP-9, CXCR3A, CXCR3B, IL-1RN and MRC was evaluated in monocyte-derived macrophages following
6 day-treatment with M-CSF- (30 ng/ml), CXCL4 (10 μg/ml) or CXCL4L1 (1 and 10 μg/ml). Results are shown as
mean (± SEM) percentage expression relative to the expression in M-CSF-treated monocytes. *p<0.05, Mann-
Whitney U test (CXCL4 or CXCL4L1 versus M-CSF); †p<0.05, Mann-Whitney U test (CXCL4 versus CXCL4L1 at
identical concentrations); #p<0.05, Mann-Whitney U test (CXCL4 vs CXCL4L1 1 μg/ml).
doi:10.1371/journal.pone.0166006.g003
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The molecular identity of receptors involved in transducing CXCL4 effects in monocytes is
still a matter of debate [15,25,31,32]. We investigated the expression levels of the candidate
receptor CXCR3 gene and found that, while CXCL4 had no effect, CXCL4L1 induced an
increase in the expression levels of CXCR3A. Similar results were obtained for CXCR3B, the
other splice variant of the CXCR3 receptor. Indeed, CXCL4-stimulated monocytes showed
lower expression levels of the CXCR3B receptor compared to M-CSF, whereas CXCL4L1-
treated monocytes showed significantly increased expression of the receptor CXCR3B. As
shown in Fig 3, IL-1RN expression was increased in CXCL4-treated monocytes, whereas in
CXCL4L1-treated monocytes the expression was slightly decreased compared to resting mac-
rophages (Fig 3). Furthermore, MRC expression was significant downregulated in CXCL4-
and CXCL4L1-treated monocytes as compared to resting macrophages. IL-1R2 expression was
below detection limit (data not shown).
Monocytes cultured in the presence of CXCL4 or CXCL4L1 differ in their
surface marker expression pattern
To further characterize the phenotype of CXCL4- and CXCL4L1-stimulated monocytes, the
expression of a panel of macrophage receptors was determined by FACS analysis. Similar to
CXCL4-treated monocytes, CXCL4L1-stimulated monocytes have a statistically significant
lower expression of CD14, the hemoglobin-haptoglobin scavenger receptor CD163, and the
chemokine receptor CCR1 when compared to M-CSF-treated monocytes (Fig 4). The expres-
sion of the costimulatory molecule CD86, which is required for T cell activation by macro-
phages, was unaffected by monocyte exposure to CXCL4 and CXCL4L1, whereas the
expression of CD1a was regulated in opposite ways in CXCL4- or CXCL4L1-treated mono-
cytes (Fig 4A). The expression of the chemokine receptors CCR2, CCR5 and CXCR3 was sig-
nificantly higher on CXCL4L1-treated monocytes as compared to CXCL4-treated monocytes
(Fig 4B). Unlike its significant downregulation reported in CXCL4-induced macrophages [18],
HLA-DR has expression levels in CXCL4L1-polarized macrophages comparable to M-CSF-
treated cells. In summary, our data show that human macrophages generated in the presence
of CXCL4 or CXCL4L1 have a distinct surface marker profile.
Differential effect of CXCL4 and CXCL4L1 on chemokine production by
monocyte-derived macrophages
One of the consequences of polarized macrophage activation is the profoundly different set of
cytokines and chemokines that is secreted [6,7]. The concentration of cytokines released in the
supernatant by CD14+ monocytes cultured for 6 days in the presence of M-CSF (30 ng/ml),
natural (1 and 10 μg/ml) or recombinant CXCL4 (10 μg/ml), or recombinant CXCL4L1 (1 and
10 μg/ml) was therefore measured by ELISA. Taking into account the number of living cells,
no difference between CXCL4 and CXCL4L1 treatment was observed in the production of
CCL18 and IL-10, both of which were released at levels significantly lower than after M-CSF
treatment (Fig 5A and 5B). On the other hand, but in agreement with previous reports,
CXCL4 enhanced the production of CCL22 [19]. Recombinant CXCL4 (10 μg/ml) and natural
CXCL4 induced the release of comparable amounts of CCL22, excluding contamination of the
natural CXCL4 preparation with other chemokines. In contrast, CXCL4L1-stimulated mono-
cytes, secreted amounts of CCL22 comparable to M-CSF-treated monocytes, with only at
10 μg/ml a minor, yet statistically significant increase (Fig 5C). Interestingly, we measured sig-
nificant production of inflammatory chemokines (CCL2 and CXCL8; Fig 5D and 5E, respec-
tively) in monocytes stimulated with CXCL4L1 (10 μg/ml), whereas CXCL4 (10 μg/ml) did
modulate inflammatory chemokine production in the same way as M-CSF. The production of
CXCL4L1 and CXCL4 Act Differently on Myeloid Cells
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TNF-α, IL-1β and CCL3 was below detection limit of the ELISA for all experimental groups
(data not shown). We conclude that human macrophages generated in the presence of CXCL4
or CXCL4L1 are significantly different in their profile of secreted cytokines.
To verify whether CXCR3 is involved in chemokine induction, we added the CXCR3 antag-
onist AMG487 during the full incubation period. This antagonist did not modulate the
CXCL4-stimulated CXCL8 release. It must be noted, however, that CXCR3 expression in
CXCL4-stimulated monocytes was significantly downregulated (Figs 3 and 4). In contrast,
CXCL4L1 upregulated CXCR3 expression and CXCL8 production by CXCL4L1-treated
monocytes was significantly inhibited in the presence of the CXCR3 antagonist AMG487
(Fig 6).
Effects of CXCL4 and CXCL4L1 on the differentiation of monocytes into
iMDDC
Having observed differential effects of CXCL4 and CXCL4L1 on monocyte differentiation into
macrophages, we investigated their effects on the differentiation of monocytes into iMDDC in
response to GM-CSF and IL-4. Two different approaches were followed. In the first set of
experiments, chemokines were added on day 4 (iMDDC A), whereas in the second set of
experiments, CXCL4 or CXCL4L1 was added on day 0, together with GM-CSF and IL-4
(iMDDC B). After 6 days of culture, iMDDC A were analyzed by flow cytometry for the
expression of different surface markers and chemokine receptors (Fig 7). We confirmed previ-
ous reports that iMDDC A express a significantly lower CD1a level in the presence of CXCL4
(10 μg/ml), compared to cells cultured in the absence of CXCL4 [31]. Neither CXCL4 nor
CXCL4L1 did change the expression of DC-SIGN/CD209, CD11b, CD80, or CD86 on
iMDDC A (Fig 7A). In contrast to CXCL4L1-stimulated monocytes, the expression of the che-
mokine receptors CCR1 and CCR5 was not affected by CXCL4L1 in iMDDC A (Fig 7B). We
next determined the effects of CXCL4 and CXCL4L1 on gene expression in iMDDC A by
qPCR (Fig 8), investigating MMPs and pro-inflammatory mediators CCL2 and iNOS.
Although at 1 μg/ml CXCL4L1 reduced CCL2 expression by iMDDC A, this observation was
not confirmed at the protein level (vide infra). At 10 μg/ml, CXCL4, nor CXCL4L1 changed
CCL2 gene expression. However, we found a significant downregulation of iNOS expression
by CXCL4 (10 μg/ml). Significant upregulation of MMP-8 was observed by both CXCL4
(10 μg/ml) and CXCL4L1 (1 and 10 μg/ml) compared to control iMDDC A, whereas MMP-9,
as well as MMP-12 expression was significantly induced by CXCL4L1 (10 μg/ml) in iMDDC
A, but remained unaffected by CXCL4 exposure.
Effects of CXCL4 and CXCL4L1 on cytokine expression in immature
MDDC
We next measured cytokine production by CXCL4-stimulated iMDDC A or CXCL4L1-stimu-
lated iMDDC A. The levels of TNF-α, IL-1β and CCL3 in the supernatants of iMDDC A were
below the ELISA detection limit (data not shown), whereas levels of CXCL8, CCL2, CCL18,
Fig 4. The expression of surface markers and chemokine receptors on macrophages after stimulation
with M-CSF, CXCL4 or CXCL4L1. Purified human CD14+ monocytes were cultured for 6 days in the presence
of recombinant M-CSF (30 ng/ml), natural CXCL4 (10 μg/ml) or recombinant CXCL4L1 (1 and 10 μg/ml). On day
6 expression of several surface markers (panel A) and chemokine receptors (panel B) was analyzed by flow
cytometry. Results from 4 to 8 independent experiments were expressed as mean fluorescence intensity and are
shown as mean (± SEM) percentages, normalized to M-CSF-treated monocytes (100%). *p<0.05, **p<0.01,
***p<0.001, Mann-Whitney U test (CXCL4 or CXCL4L1 versus M-CSF); †p<0.05,††p<0.01, Mann-Whitney U
test (CXCL4 versus CXCL4L1 at identical concentrations).
doi:10.1371/journal.pone.0166006.g004
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CCL22, and IL-10 remained unchanged by either CXCL4 or CXCL4L1 exposure as compared
to control iMDDCs (Fig 9). However, CXCL4-stimulated iMDDC B produced significantly
more CCL22 and CXCL8 than control iMDDC. CXCL4L1 did not modulate CXCL8 or
CCL22 production in either type of iMDDC (Fig 10A and 10B).
Effects of CXCL4 and CXCL4L1 on S. aureus phagocytosis by immature
MDDC
An important function of dendritic cells is to phagocytose pathogens and subsequently display
pathogen-derived antigens to lymphocytes. To determine the phagocytic capacity of
CXCL4-stimulated iMDDC A and CXCL4L1-stimulated iMDDC A, cells were exposed to
pHrodo-labeled S. aureus beads. As shown in Fig 11A, iMDDC A cultured in the presence of
CXCL4 (10 μg/ml) more actively phagocytosed the S. aureus beads (195.7±48%) compared to
Fig 5. Cytokine and chemokine production by macrophages after stimulation with M-CSF, CXCL4 or
CXCL4L1. CD14+ monocytes were differentiated in the presence of recombinant M-CSF (30 ng/ml), natural
or recombinant CXCL4 (1–10 μg/ml) or recombinant CXCL4L1 (1 and 10 μg/ml). After 6 days of culture, cell
supernatants were analyzed by ELISA to determine the amount of CCL18 (panel A), IL-10 (panel B), CCL22
(panel C), CCL2 (panel D) and CXCL8 (panel E). The measured cytokine concentrations were corrected for
the number of viable cells in the cultures at the time of sampling. The results are shown as mean ± SEM and
are pooled from 8 independent experiments. *p<0.05, **p<0.01,***p<0.001, Mann-Whitney U test (CXCL4
or CXCL4L1 versus M-CSF); ††p<0.01, †††p<0.001, Mann-Whitney U test (CXCL4 versus CXCL4L1 at
identical concentrations).
doi:10.1371/journal.pone.0166006.g005
Fig 6. Chemokine production by macrophages after stimulation with CXCL4L1 is mediated by CXCR3.
CD14+ monocytes were treated with control medium or AMG487 (100 nM) and differentiated in the presence of
recombinant M-CSF (30 ng/ml), natural CXCL4 (1–10 μg/ml) or recombinant CXCL4L1 (10 μg/ml). After 6 days of
culture, cell supernatants were analyzed by ELISA to determine the amount of CXCL8. The measured cytokine
concentrations were corrected for the number of viable cells in the cultures at the time of sampling. The results are
shown as mean ± SEM and are pooled from 8–10 independent experiments. *p<0.05, **p<0.01,***p<0.001,
Mann-Whitney U test (CXCL4 or CXCL4L1 versus M-CSF); †p<0.05, Sign test (inhibition by AMG487 of CXCL8
release).
doi:10.1371/journal.pone.0166006.g006
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Fig 7. Modulation of the surface marker and chemokine receptor expression on immature MDDC by CXCL4
and CXCL4L1. Purified human CD14+ monocytes were cultured in the presence of 50 ng/ml GM-CSF and 20 ng/ml
IL-4. On day 4, different concentrations of natural CXCL4 (10 μg/ml) or recombinant CXCL4L1 (1 and 10 μg/ml)
were added to the cultures. On day 6 (i.e. 2 days after addition of chemokines), iMDDCs A were collected and the
expression of surface markers (panel A) and chemokine receptors (panel B) was analyzed by flow cytometry.
Results from 3 to 7 independent experiments were expressed as mean fluorescence intensity and are shown as
mean (± SEM) percentages, normalized to iMDDC cultured in the absence (100%) of CXCL4 or CXCL4L1.
**p<0.01, Mann-Whitney U test (CXCL4 versus untreated); †p<0.05, Mann-Whitney U test (CXCL4 versus
CXCL4L1 at identical concentrations).
doi:10.1371/journal.pone.0166006.g007
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control iMDDC. In contrast, stimulation with CXCL4L1 (10 μg/ml) inhibited the phagocytic
capacity of iMDDC A (35.5±11.4%). In contrast, CXCL4L1- and CXCL4-stimulated iMDDC
B phagocytosed S. aureus beads as efficiently as control iMDDC (Fig 11B).
Fig 8. Effects of CXCL4 and CXCL4L1 on gene expression in differentiated immature MDDC. Relative
expression of CCL2, iNOS, MMP-8, MMP-9, MMP-12 and VEGF was evaluated in iMDDC A following treatment
with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml) in the absence (Co) or presence of CXCL4- (10 μg/ml) or CXCL4L1 (1
and 10 μg/ml). The results are shown as mean (± SEM) percentage expression relative to the expression on
untreated iMDDC. *p<0.05, Mann-Whitney U test (CXCL4 or CXCL4L1 versus CO); †p<0.05, Mann-Whitney U test
(CXCL4 versus CXCL4L1 at identical concentrations).
doi:10.1371/journal.pone.0166006.g008
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Discussion
Inflammatory chemokines, e.g. CCL3, can mediate a short-term biological response of mono-
cytes such as chemotaxis, without promoting their survival. Other chemokines, such as
CXCL4, play, like M-CSF, a role in long-term regulatory processes by inhibiting apoptosis and
inducing differentiation of monocytes into macrophages [18–20]. However, compared to
M-CSF-induced macrophages, CXCL4 induces a macrophage phenotype, which shares simi-
larities with both M1 and M2 macrophages [19]. In the present study, we report on the differ-
ential effect of CXCL4 and CXCL4L1 on monocyte survival and differentiation. In contrast to
CXCL4-induced macrophages, CD14+ monocytes stimulated with CXCL4L1 were far less
numerous, their numbers being comparable to those of unstimulated monocytes. Unlike
CXCL4-stimulated monocytes [18], CXCL4L1-treated cells did not display significant downre-
gulation of HLA-DR compared to M-CSF-induced macrophages, which suggests that their
antigen-presenting capacity is preserved. On the other hand, a number of expression markers
(e.g. CD11b, CD14, CD86, CD163) was not differentially expressed between CXCL4- and
CXCL4L1-stimulated monocytes. CXCL4-induced macrophages have been reported to express
considerably less surface CCR2 as compared to M-CSF-exposed cells [32]. We found, com-
pared to CXCL4-induced macrophages and M-CSF-exposed cells, CXCL4L1-stimulated
monocytes to display higher expression levels of the inflammatory chemokine receptors CCR2
and CCR5, suggesting that CXCL4L1 promotes a higher responsiveness to inflammatory
CC chemokines, such as CCL2 and CCL3. In addition, the amount of CXCL8 and CCL2
(M1 marker) released was significantly higher in CXCL4L1-stimulated monocytes than in
CXCL4-treated monocytes, whereas the concentration of CCL22 (M2 marker) was lower [6].
Though we could not confirm upregulated CCL18 synthesis, we reproduced data reported by
Gleissner et al. [19], who detected higher production of CCL22 in CXCL4-stimulated mono-
cytes. Based on Fig 6, we postulate that the CXCL4-induced production of CXCL8 is indepen-
dent of CXCR3, whereas CXCR3 is implicated in the CXCL4L1-stimulated CXCL8 production
by macrophages. Kasper and Petersen [13] already suggested that glycosaminoglycans mediate
the CXCL4-induced monocyte survival. Expression of iNOS (M1 marker) in CXCL4L1-stimu-
lated monocytes was decreased compared to M-CSF-treated monocytes, whereas the levels of
HMOX1 (M2 marker) expression upon CXCL4L1 stimulation were significantly increased
compared to M-CSF stimulation. CD163 is a scavenger receptor required for effective hemo-
globin clearance after plaque hemorrhage, and its engagement by hemoglobin-haptoglobin
complexes results in upregulation of HMOX1, an enzyme with anti-inflammatory effects and
linked to atheroprotection [33]. CXCL4 promotes atherogenesis by suppressing CD163 in
macrophages [20]. Although CD163 expression was also downregulated on CXCL4L1-stimu-
lated monocytes compared to resting macrophages, HMOX1 expression in CXCL4L1-stimu-
lated monocytes was increased compared to resting macrophages, whereas its expression was
lower in CXCL4-induced macrophages. The lower expression of IL-1RN in CXCL4L1-treated
monocytes, compared to CXCL4-treated monocytes, is in line with the more inflammatory
phenotype of macrophages generated in the presence of CXCL4L1.
MMPs are major macrophage products with important immunological functions, includ-
ing extracellular matrix remodeling and modulation of chemokine activity by post-
Fig 9. Cytokine and chemokine production by iMDDC A after stimulation with CXCL4 or CXCL4L1.
Purified human CD14+ monocytes were cultured in the presence of 50 ng/ml GM-CSF and 20 ng/ml IL-4. On
day 4, different concentrations of natural CXCL4 (10 μg/ml) or recombinant CXCL4L1 (0.1, 1 and 10 μg/ml)
were added to the cultures. Cell supernatants were collected after 6 days of culture. The amount of CCL18
(panel A), IL-10 (panel B), CCL22 (panel C), CCL2 (panel D) and CXCL8 (panel E) produced was measured
by sandwich ELISAs. The results (mean ± SEM) are derived from 5–7 independent experiments.
doi:10.1371/journal.pone.0166006.g009
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Fig 10. Chemokine production by iMDDC B after a 6 day-treatment with CXCL4 or CXCL4L1. Purified human
CD14+ monocytes were cultured for 6 days in the presence of 50 ng/ml GM-CSF and 20 ng/ml IL-4. From the start
of the culture different concentrations of natural CXCL4 (10 μg/ml) or recombinant CXCL4L1 (0.1, 1 and 10 μg/ml)
were added (iMDDC B). Cell supernatants were collected after 6 days of culture. The amount of CCL22 (panel A)
and CXCL8 (panel B) produced was measured by sandwich ELISAs. The results (mean ± SEM) are derived from 6
independent experiments. *p<0.05, **p<0.01, Mann-Whitney U test (CXCL4 or CXCL4L1 versus M-CSF);
†p<0.05, Mann-Whitney U test (CXCL4 versus CXCL4L1 at identical concentrations).
doi:10.1371/journal.pone.0166006.g010
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Fig 11. CXCL4- or CXCL4L1-stimulated phagocytosis of S. aureus by dendritic cells. CD14+ monocytes were
cultured in the presence of 50 ng/ml GM-CSF and 20 ng/ml IL-4. On day 4 (panel A; iMDDC A) or day 0 (panel B;
iMDDC B), different concentrations of natural CXCL4 (10 μg/ml) or recombinant CXCL4L1 (0.1, 1 and 10 μg/ml)
were added. After 6 days of culture, DC were exposed to pHrodo-labeled S. aureus as described in Methods. The
phagocytic capacity of CXCL4- and CXCL4L1-stimulated iMDDC was assessed by flow cytometry and is expressed
relative to the net fluorescence of control iMDDC, differentiated with GM-CSF plus IL-4 without addition of
chemokine (Co). Results of 3–4 independent experiments, each performed in duplicate are shown. *p<0.05; Mann-
Whitney U test (CXCL4 versus M-CSF) - †p<0.05; Mann-Whitney U test (CXCL4 versus CXCL4L1).
doi:10.1371/journal.pone.0166006.g011
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translational processing [19,34–36]. When comparing MMP gene expression in
CXCL4L1-treated monocytes with that of CXCL4-induced macrophages, we found some
MMPs being expressed in CXCL4-stimulated monocytes at significantly higher levels (e.g.
MMP-9) whereas others showing significantly higher expression in CXCL4L1-differentiated
macrophages (e.g. MMP-2 and MMP-8). It is reasonable to assume that the two chemokine
variants have differential effects on macrophage-dependent MMP activities, though these
results do not allow for a direct estimate of functional effects as the enzymatic activity of
MMPs is tightly regulated at several levels, including transcriptional control and post-transla-
tional inhibition by tissue inhibitors of metalloproteinases (TIMPs) [37,38].
Dendritic cells are crucial initiators of adaptive immune responses. A range of different
inflammatory stimuli can induce monocyte differentiation to dendritic cells, and not surpris-
ingly, iMDDC generated by different inflammatory stimuli may differ in their functions [39].
We here report that CXCL4L1 also influences the differentiation of monocytes into dendritic
cells, and specifically the expression of MMP genes. As reported previously, CXCL4 signifi-
cantly inhibited the expression of CD1a on iMDDC [31]. In contrast, the expression of CD1a
on iMDDC A differentiated with CXCL4L1 was comparable to GM-CSF/IL-4 stimulated
iMDDC. Expression levels of CD80, CD11b, and CD209 were not influenced by CXCL4 or
CXCL4L1. Differently from previous reports, this was also observed for CD86 levels [31], a dis-
crepancy possibly due to different time length of CXCL4 exposure.
Different stages of monocyte differentiation are characterized by different repertoires of
GPCR. For instance, CCR2 is rapidly downregulated during monocyte differentiation to
iMDDC, although the expression of CCR1 and CCR5 is upregulated [28]. LPS and IFN-γ up-
regulate CCR7 and downregulate CCR1 in mature dendritic cells [40,41]. Presumably, this
reciprocal regulation underlies the trafficking of dendritic cells to lymph nodes through lym-
phatic vessels to present antigen in the lymph nodes. However, CXCL4 and CXCL4L1 did not
affect chemokine receptors expression on iMDDC A. Moreover, the cytokine production pro-
file of CXCL4- or CXCL4L1-differentiated iMDDC A was similar, confirming previously pub-
lished data describing that CXCL4-treated DC secreted similar amounts of IL-10 compared to
control dendritic cells [31]. However, the effect of CXCL4 or CXCL4L1 on the chemokine
footprint and/or phagocytic capacity of iMDDCs depended on the time of exposure of
iMDDCs to CXCL4 or CXCL4L1.
In the present study, we provide insight into the effect of CXCL4 and CXCL4L1 on mono-
cyte differentiation into macrophages and dendritic cells. We can conclude that differently
from CXCL4, CXCL4L1 is not a survival factor for monocytes and that the two chemokine var-
iants also induce distinct macrophage phenotypes different from M1 and M2, with more pro-
nounced inflammatory traits for CXCL4L1. Moreover, iMDDC A developed in the presence
of CXCL4 showed a phenotype different from that seen in CXCL4L1 differentiated iMDDC A,
i.e. enhanced phagocytic capacity and downregulation of expression of certain surface markers
(e.g. CD1a) and enzymes (e.g. MMP-9 and MMP-12). In contrast, in CXCL4-induced macro-
phages MMP-9 expression was upregulated. Taken together, these results candidate CXCL4
and CXCL4L1 as distinct platelet-derived mediators during inflammatory reactions. However,
it is hard to explore the in vivo consequences of these in vitro observations, as the two CXCL4
and CXCL4L1 genes are only present in primates and mice only have one CXCL4 gene. The
murine CXCL4 might combine properties of human CXCL4 and CXCL4L1.
Nevertheless, it has been previously suggested that modulation of macrophage heterogene-
ity by CXCL4 may represent an interesting therapeutic approach [42–44]. In atherosclerosis
for example, driving macrophages towards an atheroprotective phenotype by treatments tar-
geting platelet-derived chemokines may help to limit disease progression and improve long-
term prognosis in patients with cardiovascular diseases [42–44]. Furthermore, it is generally
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accepted that macrophages are crucial stromal cells influencing tumor development [7–10]. In
view of the effect of CXCL4 and CXCL4L1 on macrophages and dendritic cells, the tumor
microenvironment can also be shaped by those platelet chemokines. We observed selective
CXCL4L1 expression in colon cancer patients by immunohistochemistry in tumor cells [45]
but the number of specimens analyzed was too low to allow correlation analyses with tumor
stage or survival. Furuya et al. detected high levels of CXCL4 and CXCL4L1 mRNA in endo-
metriosis, an inflammatory status that can evolve to ovarian cancer [46]. Interestingly, CXCL4
(and/or CXCL4L1, because a non-discriminating antibody was used) expression decreased in
tumor-associated macrophages (TAMs) of ovarian cancers arising in endometriosis [46]. Simi-
larly, CXCL4 production decreased in lung Ly6G+CD11b+ cells in a murine model of breast
cancer [47]. Concomitant with evolution from normal lungs towards lungs carrying breast
cancer or melanoma metastases, murine CXCL4 diminished at the mRNA and protein level in
Ly6G+CD11b+ cells. In breast cancer patients, global tumor CXCL4 mRNA expression levels
were negatively correlated with tumor stage and positively correlated with patient survival
[47]. In conclusion, the multipotent nature of CXCL4 and CXCL4L1 implies that those platelet
chemokines affect, apart from angiogenesis, also lymphocyte recruitment and monocyte/mac-
rophage survival or polarization in the tumor stroma.
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